Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactoplantibacillus plantarum CECT7527 + lactoplantibacillus plantarum CECT7528 + lactoplantibacillus plantarum CECT7529 + monacolin k
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A combination product containing the probiotic strains **Lactoplantibacillus plantarum CECT7527, CECT7528, CECT7529** and **monacolin K**. The probiotic strains are Gram-positive, non-pathogenic bacteria originally isolated from healthy infants and are recognized for their ability to reduce cholesterol in vitro and in human clinical trials. This effect is attributed to high bile salt hydrolase activity, which increases bile acid excretion and cholesterol assimilation, contributing to lower blood LDL and total cholesterol levels. **Monacolin K** is the principal bioactive from red yeast rice, chemically identical to lovastatin, and acts as an HMG-CoA reductase inhibitor to reduce cholesterol synthesis in the liver. The combination is mainly indicated for hypercholesterolemia, especially in individuals intolerant to statins, and has demonstrated safety and tolerability in clinical use[1][5][6][7].
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on lactoplantibacillus plantarum CECT7527 + lactoplantibacillus plantarum CECT7528 + lactoplantibacillus plantarum CECT7529 + monacolin k.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactoplantibacillus plantarum CECT7527 + lactoplantibacillus plantarum CECT7528 + lactoplantibacillus plantarum CECT7529 + monacolin k.